Information Provided By: 
Fly News Breaks for May 19, 2015
ICPT
May 19, 2015 | 10:07 EDT
Cowen said Intercept's is reacting negatively to the OCA Phase 3 in NASH trial design of 2500 patients, which is larger than expected. The firm said the primary endpoint will be driven by 1400 patients and shouldn't impact timeliness given recent trace records in NASH trial enrollments. Cowen said the primary endpoint of fibrosis and NASH resolution are entirely consistent with its expectations and finds it encouraging based on Phase II.
News For ICPT From the Last 2 Days
There are no results for your query ICPT
